{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013477","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.669747+00:00","generated_at":"2026-05-15T08:23:47.067823+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M","bullets":["PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.","GAAP net loss attributable to common stockholders $1.8M ($2.05 per share diluted); non-GAAP adjusted loss $0.9M ($1.05 per share).","Lucid Diagnostics recognized $1.5M EsoGuard revenue in Q4 2025, processed 3,664 tests; awarded VA contract for ~9M veterans.","Veris Health completed EHR integration with OSU James Cancer Hospital; targeting late 2026 FDA submission for implantable monitor.","PAVmed appointed Joseph Virgilio as CBO of Medical Devices and licensed endoscopic esophageal imaging technology from Duke University."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013477","json":"https://secwatch.observer/filing/0001493152-26-013477.json","markdown":"https://secwatch.observer/filing/0001493152-26-013477.md","text":"https://secwatch.observer/filing/0001493152-26-013477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:23:47.067823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02bf8d36a9ff2814e3f610cc77d260644c4ce078","claim":"PAVmed Inc. reported financial results for year ended December 31, 2025.","evidence_excerpt":"PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"da2abf9e5c895c5d504df4fb50d754c6ae193929","claim":"PAVmed Inc. reported three months ended December 31, 2025 results: net income approximately $1.8 million, EPS $(2.05) per common share on a diluted basis.","evidence_excerpt":"For the three months ended December 31, 2025, Operating expenses were approximately $6.9 million which include stock-based compensation expenses of $0.3 million. GAAP net loss attributable to common stockholders was approximately $1.8 million, or $(2.05) per common share on a diluted basis.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1624326/000149315226013477/0001493152-26-013477-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2025"},{"label":"Net income","value":"approximately $1.8 million"},{"label":"EPS","value":"$(2.05) per common share on a diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}